4 analysts' median target is $415[FMP target], stock is $306, +35.7% upside potential. After Q1 +0.7% EPS beat[FMP earnings], the stock moved +6.7%.
B+ = MoonshotScore 36[9-pillar formula] + Council 4/6[6-lens rule]. Form 4: 0 transactions[FMP Form 4].
Q4 consensus: revenue $81.1B[FMP est], EPS $4.80[FMP est]. 8 consecutive quarters of beat[FMP earnings].
Q1 EPS +0.7% beat[FMP] but the stock +6.7% D+1[FMP D+1]. James Cleary promised $119.4M CapEx + a sequential decline in Q4 during the Q1 earnings call[James Cleary capex transcript].
Watchlist
Fy26 Operating Income Guidance
fy26_operating_income_guidance
Cencora is raising its fiscal 2026 guidance to reflect year-over-year adjusted operating income growth of 11.5% to 13.5%, driven by the contribution from OneOncology.
"To reflect our performance and the contribution from our recently completed acquisition of OneOncology, we are raising our fiscal 2026 guidance to reflect year-over-year adjusted operating income growth of 11.5% to 13.5%."
- Robert Mauch, President and CEO - Q1 FY26 Earnings Call - February 4, 2026
Us Healthcare Solutions Growth
us_healthcare_solutions_growth
The US healthcare solutions segment operating income growth expectation is increased to a range of 14% to 16% due to the strong performance and the acquisition of OneOncology.
"This is primarily driven by our increased growth expectations for the US healthcare solutions segment, where we now expect operating income growth to be in the range of 14% to 16% due to our acquisition of OneOncology and the continued strong execution and performance of the segment."
- James Cleary, Executive Vice President and CFO - Q1 FY26 Earnings Call - February 4, 2026
Us Healthcare Solutions Revenue
us_healthcare_solutions_revenue
US healthcare solutions revenue was $76.2 billion, up 5% as we continue to see good volumes and revenue growth across our customer segments, including growth in GLP-1s, and in specialty sales to health systems and physicians.
"US healthcare solutions revenue was $76.2 billion, up 5% as we continue to see good volumes and revenue growth across our customer segments, including growth in GLP-1s, and in specialty sales to health systems and physicians."
- James Cleary, Executive Vice President and CFO - Q1 FY26 Earnings Call - February 4, 2026
Glp 1 Sales Growth
glp_1_sales_growth
In the quarter, we continued to see strong sales growth in the US for GLP-1 products, which increased by $1 billion or 11% over the prior year quarter.
"In the quarter, we continued to see strong sales growth in the US for GLP-1 products, which increased by $1 billion or 11% over the prior year quarter."
- James Cleary, Executive Vice President and CFO - Q1 FY26 Earnings Call - February 4, 2026
International Healthcare Solutions Outlook
international_healthcare_solutions_outlook
In the International Healthcare Solutions segment, revenue growth is now expected to be in the range of 7% to 9% on an as-reported basis to reflect the weakening of the US dollar against many currencies.
"In the International Healthcare Solutions segment, we now expect revenue growth to be in the range of 7% to 9% on an as-reported basis to reflect the weakening of the US dollar against many currencies."
- James Cleary, Executive Vice President and CFO - Q1 FY26 Earnings Call - February 4, 2026
Stock Expert AI - Methodology
9-pillar methodology. Revenue Growth and News Sentiment strong. Gross Margin weak.
How is it calculated? ->6 investor frameworks. 4 bullish (Ray Dalio, Klarman, Buffett, Munger), 1 bearish (Ken Griffin), 1 neutral (Jim Simons).
How is it calculated? ->Quality business, discounted price.
How is it calculated? ->Past Performance
Q1 (February 4, 2026): EPS $4.08 vs $4.05 est[FMP], +0.7% beat. D+1 movement: +6.7%[FMP D+1]. Decline despite beat - market reacted to guidance, not numbers.
Q1: EPS $4.08 vs $4.05 beat[FMP], stock +6.7% D+1[FMP].
No RPO/backlog concentration disclosed in Q1 earnings call.
Q1 CapEx $119.4M[FMP cashflow]. Q1 op margin 1.2%[FMP op margin] - this level in Q4 is sensitive to CapEx revision risk.
Not advice - a structural framework for earnings night. Decision discipline is yours.
Market Outlook
You read it in 5 minutes. When the numbers come out on Wednesday evening - you know what you're looking at.
Data arrives at night. The framework is ready now.
Data arrives on Wednesday evening. The framework is ready on this page: Q4 EPS threshold $4.80[FMP], CapEx threshold "below $119.4M"[James Cleary]. Two anchors, three scenarios.
Comparison Stock Expert AI Pro $24/month ($240/year), 77% cheaper than the total of three earnings-tracking tools ($1,059/year -> $240/year).
Seeking Alpha $299/yr - analyst opinions + earnings coverage TipRanks $360/yr - Smart Score (1-10) + analyst consensus + insider trades Trendspider $400/yr - AI pattern detection + automated TA + multi-timeframe alerts
Prices as of April 2026. Sources: seekingalpha.com/subscriptions - tipranks.com/pricing - trendspider.com/pricing
Stock Expert AI Pro: $24/month ($240/year). Council 7-lens analysis + MoonshotScore 9-pillar + Insider tracker + Technical levels - all in one platform, for every stock.
Educational tool, not investment advice. Past performance does not guarantee future results.
Calendar
DATA GAP: Events not in the FMP /stable/calendar feed - Investor day, analyst day, product launches, regulatory dates. These require company IR page scraping or manual calendar entry.
This COR (COR) earnings preview covers the analyst consensus, key catalysts, and what to watch on the earnings call.
Consensus EPS, revenue guidance, segment growth rates, and the tone of management commentary — the full breakdown with sources is on this page.